Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) EBITDA Margin (2020 - 2025)

Pulse Biosciences has reported EBITDA Margin over the past 4 years, most recently at 22540.7% for Q3 2025.

  • Quarterly results put EBITDA Margin at 22540.7% for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was 86898.84% (changed N/A YoY), and the annual figure for FY2022 was 8357.86%, down 381079.0%.
  • EBITDA Margin for Q3 2025 was 22540.7% at Pulse Biosciences, down from 4665.33% in the prior quarter.
  • Over the last five years, EBITDA Margin for PLSE hit a ceiling of 16349.12% in Q1 2021 and a floor of 22540.7% in Q3 2025.
  • Median EBITDA Margin over the past 3 years was 2488.15% (2021), compared with a mean of 2366.55%.
  • Biggest five-year swings in EBITDA Margin: surged 22733366bps in 2021 and later crashed -2066737bps in 2022.
  • Pulse Biosciences' EBITDA Margin stood at 1866.34% in 2021, then tumbled by -150bps to 4665.33% in 2022, then crashed by -383bps to 22540.7% in 2025.
  • The last three reported values for EBITDA Margin were 22540.7% (Q3 2025), 4665.33% (Q2 2022), and 4318.25% (Q1 2022) per Business Quant data.